Cover Image
市場調查報告書

EpiCast Report:前列腺肥大症 (BPH) - 到2024年的流行病學預測

EpiCast Report: Benign Prostatic Hyperplasia - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 341955
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:前列腺肥大症 (BPH) - 到2024年的流行病學預測 EpiCast Report: Benign Prostatic Hyperplasia - Epidemiology Forecast to 2024
出版日期: 2015年09月11日 內容資訊: 英文 28 Pages
簡介

前列腺肥大症 (良性攝護腺肥大症:BPH) ,是包圍尿道的前列腺組織的非惡性增生,引起下部尿路症狀 (LUTS)帶來尿道口的狹窄。全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)確診出前列腺肥大症 (BPH) 的患者數,預計今後10年從2014年的16,095,043人,到18,884,244人,增加1.73%。

本報告提供全球主要7個國家的前列腺肥大症 (BPH) 調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:確診的患者數
  • BPH的流行病學預測
    • BPH和確診的患者數
    • BPH和確診的患者數 (各年齡)
    • BPH和確診的患者數:各前列腺症狀評分IPSS
    • BPH和確診的患者數 (年齡標準化)
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER087-15

Benign prostatic hyperplasia (BPH) is a nonmalignant growth of prostatic tissue that surrounds the urethra, and leads to constriction of the urethral opening, which gives rise to lower urinary tract symptoms (LUTS). BPH is commonly observed in men ages 40 years and above. The diagnosis of BPH is made on clinical basis by the presence of LUTS and benign prostatic enlargement and the absence of any other identifiable causes.

The diagnosed prevalent cases of BPH in the 7MM increased from 16,095,043 cases in 2014 to 18,884,244 cases in 2024, at an annual growth rate (AGR) of 1.73% during the forecast period. Among the 7MM in 2024, the US will have the highest number of diagnosed prevalent cases of BPH, with 6,182,362 diagnosed prevalent cases, whereas Spain will have the lowest number, with 1,599,508 diagnosed prevalent cases. In the 5EU, Germany will have the highest number of diagnosed prevalent cases of BPH in 2024, with 2,512,517 diagnosed prevalent cases, and Spain will have the lowest number, with 1,599,508 diagnosed prevalent cases.

GlobalData's epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of BPH in the 7MM during 2014-2024.To construct the 10-year epidemiological forecast for the diagnosed prevalent cases of BPH in the 7MM, GlobalData epidemiologists used data available from population based studies in the 7MM. For the US, GlobalData epidemiologists used data available from a study that provided a nationally representative number of diagnosed BPH cases in the US men, which was further segmented into the age-specific diagnosed BPH cases. GlobalData epidemiologists used the data available from population based studies in the UK and Italy to calculate the diagnosed prevalence of BPH in the 5EU. Due to lack of data on the diagnosed prevalence of BPH in Japan, GlobalData epidemiologists used a study from Korea and applied the age-specific distribution of histological prevalence from a US study to calculate the age-specific diagnosed prevalence of BPH in Korea, and then used it as proxy for Japan.

Scope

  • The benign prostatic hyperplasia (BPH) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Benign Prostatic Hyperplasia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of BPH segmented by age (10-year intervals starting at ages 40 years and ending at =85 years). The diagnosed prevalent cases of BPH were segmented into mild, moderate, and severe categories as per the IPSS criteria defined by the American Urological Association.
  • The BPH epidemiology report is were written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global BPH market.
  • Quantify patient populations in the global BPH market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and disease severity category that present the best opportunities for BPH therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases
  • 3.5. Epidemiological Forecast for BPH (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of BPH
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of BPH
    • 3.5.3. Diagnosed Prevalent Cases of BPH by Severity Using IPSS Criteria
    • 3.5.4. Age Standardized Diagnosed Prevalence of BPH (%)
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for BPH
  • Table 2: 7MM, Sources of Epidemiological Data Used in the Forecast for BPH Diagnosed Prevalence Data
  • Table 3: 7MM, Diagnosed Prevalent Cases of BPH, Ages ≥40 Years, Men (N), 2014-2024
  • Table 4: 7MM, Age-Specific Diagnosed Prevalent Cases of BPH, Ages ≥40 Years, Men, N (Row %), 2014

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of BPH, Ages ≥40 Years, Men (N), 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of BPH, Ages ≥40 years, Men (N), 2014
  • Figure 3: 7MM, Severity Profile of Diagnosed Prevalent Cases of BPH, Ages ≥40 years, Men (N), 2014
  • Figure 4: 7MM, Age Standardized Prevalence of BPH, Ages ≥40 years, Men (%), 2014
Back to Top